Browse studies

Find your next paid study

847 recruiting studies matching your filters

FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined With Enfortumab Vedotin and Pembrolizumab in Adults With Untreated Locally Advanced or Metastatic Urothelial Carcinoma With an FGFR3 Genetic Alteration

The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer t…

Carcinoma, Transitional CellUrinary Bladder NeoplasmsNeoplasm Metastasis

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT07218380

Phase 3

FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer.

This is a clinical study that has three parts. It is testing a potential new medicine called Sofetabart Mipitecan (Sofe-M) for people with certain types of ova…

Ovarian NeoplasmsFallopian Tube NeoplasmsPeritoneal Neoplasms+1 more

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT07213804

Observational

A Pilot Trial of a Community-Based Strategy to Improve Colorectal and Breast Cancer Screening

The goal of the proposed study is to conduct a pilot randomized controlled trial (RCT) of Chi gung, a community-based intervention using peer education and tai…

Colorectal NeoplasmsBreast Neoplasms

Estimated

~$10 – $6,250

Icahn School of Medicine at Mount SinaiNCT07748377

Phase 2

preEMBER: A Phase 2, Open-label Study Evaluating Imlunestrant in Premenopausal Women With Estrogen Receptor-Positive, HER2-Negative Breast Cancer

This study will include two groups of patients: Cohort 1 and Cohort 2. Cohort 1: will help researchers learn how a medicine called imlunestrant (LY3484356) af…

Breast Neoplasms

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT07287098

Phase 2

A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who Are Considered High-Risk (Adverse) Acute Myeloid Leukemia As Determined by MYELOMATCH; A MYELOMATCH SubStudy

This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimen…

Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative NeoplasmAcute Myeloid Leukemia Post Cytotoxic Therapy+1 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)

Phase 1

A Phase 1a/b Multicenter, Open-Label Trial to Evaluate Safety, Tolerability, and Dosimetry of LY4257496, a GRPR-Targeted Radioligand Therapy, in Adults With GRPR-Positive Advanced Solid Tumors (OMNIRAY)

The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination …

Breast NeoplasmsColorectal NeoplasmsProstate Neoplasm+4 more

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT07114601

Phase 1

Phase I Trial of 5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in Patients With Advanced Solid Tumors

Background: Blood, tissue, and tumor cells contain genes. Genes are made up of DNA. DNA is the "instruction book" for each cell. In some people with cancer, t…

NeoplasmsSolid Tumors

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT03366116

Population-Based Analysis of Neoplastic Changes in Cystic Lesions of the Pancreas.

Pancreatic cysts are found incidentally on 15-50% of CT and MRIs for all indications and their prevalence is increasing. Many of these cysts may be precursors …

Pancreatic CystPancreatic NeoplasmsPancreatic Cancer+5 more

Estimated

~$10 – $675

University of California, San FranciscoNCT04291651

Phase 2

A Phase II Trial of Trifluridine/Tipiracil Plus Oxaliplatin in Patients With Advanced or Metastatic Biliary Tract Cancer Following First-Line Therapy

Participants are eligible for this study who were treated for advanced biliary tract cancer (BTC) but the treatment either did not make the cancer better or is…

Biliary Tract CancerBiliary Tract NeoplasmsCholangiocarcinoma+2 more

Estimated

~$10 – $6,250

Case Comprehensive Cancer CenterNCT07146646

Phase 3

A Phase 2, Randomized, Open-Label Dose Optimization and Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY4064809 Combined With a CDK4/6 Inhibitor and Endocrine Therapy in Adults With HR+, HER2-Advanced Breast Cancer With a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)

The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment f…

Breast NeoplasmsNeoplasm Metastasis

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT07174336

Phase 1

A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy With LY4337713 in Adults With FAP-Positive Solid Tumors (FiREBOLT)

This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a p…

Ovarian NeoplasmsBreast NeoplasmsPancreatic Intraductal Neoplasms+4 more

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT07213791

Observational

Empowering Patients' Lung Cancer Screening Uptake (Empower LCS/Call+): A Multi-Site Pilot Randomized Controlled Trial

Lung cancer screening (LCS) with low-dose computed tomography (LDCT) can reduce the risk of dying from lung cancer, but many people who are eligible for screen…

Lung Cancer ScreeningLung NeoplasmsSmoking ( Cigarette)+1 more

Estimated

~$10 – $6,250

University of California, IrvineNCT07711691